New injection aims to ease lung pressure in scarred lungs

NCT ID NCT07473700

Recruiting now Disease control Sponsor: Tectonic Operating Company, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This phase 2 trial tests an injected drug called TX000045 in 25 people who have high blood pressure in the lungs due to scarring lung disease. The main goal is to see if the drug lowers lung blood pressure and is safe over 16 weeks. Researchers will also check for side effects and changes in heart function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TX000045 (injected drug)
What this could lead to: If it works, this could point toward a new treatment to lower blood pressure in the lungs for people with lung scarring.
What could go wrong: This is a small, early-phase trial with only 25 people, so results may not apply widely. The drug could cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary hypertension pulmonary hypertension owing to lung disease and/or hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION, PULMONARY LUNG DISEASES, INTERSTITIAL

Contacts and locations

Locations

Allen Park
NOT_YET_RECRUITING

Allen Park, Michigan, 48101, United States
Barcelona
NOT_YET_RECRUITING

Barcelona, 08002, Spain
Belgrade
NOT_YET_RECRUITING

Belgrade, 11000, Serbia
Bucharest
NOT_YET_RECRUITING

Bucharest, 50159, Romania
Gyeonggi-Do
NOT_YET_RECRUITING

Gyeonggi-do, 14353, South Korea
Idaho
NOT_YET_RECRUITING

Idaho Falls, Idaho, 83706, United States
Krakow
NOT_YET_RECRUITING

Krakow, 31-202, Poland
Lublin
NOT_YET_RECRUITING

Lublin, 20-950, Poland
Madrid
NOT_YET_RECRUITING

Madrid, 28046, Spain
Niš
NOT_YET_RECRUITING

Niš, 18000, Serbia
Phoenix
RECRUITING

Phoenix, Arizona, 85020, United States
San Francisco
RECRUITING

San Francisco, California, 94143, United States
Santander
NOT_YET_RECRUITING

Santander, 39011, Spain
Seoul
NOT_YET_RECRUITING

Seoul, 05505, South Korea
Sremska Kamenica
NOT_YET_RECRUITING

Kamenitz, 21204, Serbia
Wroclaw
NOT_YET_RECRUITING

Wroclaw, 50-556, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.